نتایج جستجو برای: sflt

تعداد نتایج: 664  

2017
Tian-Xiao Hu Gang Wang Wei Wu Lu Gao Qing-Ying Tan Jing Wang

Hydrogen sulfide (H2S) has recently been identified as an endogenous gaseous signaling molecule. The aim of the present study was to investigate the effect of H2S on high glucose- (HG-) induced ADAM17 expression and sFlt-1 production in 3T3-L1 adipocytes. Firstly, we found that HG DMEM upregulated the expression of ADAM17 and production of sFlt-1 in 3T3-L1 adipocytes. Knocking down ADAM17 atten...

Journal: :American journal of physiology. Gastrointestinal and liver physiology 2005
Y Motomura H Kanbayashi W I Khan Y Deng P A Blennerhassett P J Margetts J Gauldie K Egashira S M Collins

Peritoneal fibrosis formation is a consequence of inflammation/injury and a significant medical problem to be solved. The effects of soluble VEGF receptor type I (sFlt-1) gene transfer on experimental peritoneal fibrosis were examined and compared with soluble transforming growth factor-beta (TGF-beta) receptor type II (sTGF beta RII) gene transfer. Male C57BL/6 mice were injected with 1.5 x 10...

Journal: :Diabetes 2008
Ching-Hsin Ku Kathryn E. White Alessandra Dei Cas Anthea Hayward Zoe Webster Rudy Bilous Sally Marshall Giancarlo Viberti Luigi Gnudi

OBJECTIVE Podocyte-specific, doxycycline (DOX)-inducible overexpression of soluble vascular endothelial growth factor (VEGF) receptor-1 (sFlt-1) in adult mice was used to investigate the role of the VEGF-A/VEGF receptor (VEGFR) system in diabetic glomerulopathy. RESEARCH DESIGN AND METHODS We studied nondiabetic and diabetic transgenic mice and wild-type controls treated with vehicle (VEH) or...

2011
Marni Jacobs Natasha Nassar Christine L Roberts Ruth Hadfield Jonathan M Morris Anthony W Ashton

Angiogenic factors are involved in formation of new blood vessels required for placental development and function; and critical for fetal growth and development. Soluble fms-like tyrosine kinase 1(sFlt-1) is an anti-angiogenic protein that inhibits formation of new blood vessels resulting in potential pregnancy complications. The objective of this study was to undertake a systematic review to a...

2000
Funmi M. Belgore Andrew D. Blann Gregory Y.H. Lip

Exogenous VEGF To the Editor: Results from the VEGF in Ischemia for Vascular Angiogenesis (VIVA) clinical trial, which demonstrated the therapeutic use of vascular endothelial growth factor (VEGF) in angina, were presented at the 48th Scientific Sessions of the American College of Cardiology.1 These results indicated that no significant difference existed in the symptoms or clinical events of p...

2014
Reshef Tal David B Seifer Richard V Grazi Henry E Malter

BACKGROUND Polycystic ovarian syndrome (PCOS) is characterized by increased ovarian angiogenesis and vascularity. Accumulating evidence indicates that vascular endothelial growth factor (VEGF) is increased in PCOS and may play an important role in these vascular changes and the pathogenesis of this disease. Placental growth factor (PlGF), a VEGF family member, has not been previously characteri...

Journal: :Hypertension 2016
Frank T Spradley Adelene Y Tan Woo S Joo Garrett Daniels Paul Kussie S Ananth Karumanchi Joey P Granger

Preeclampsia is a pregnancy-specific disorder of new-onset hypertension. Unfortunately, the most effective treatment is early delivery of the fetus and placenta. Placental ischemia appears central to the pathogenesis of preeclampsia because placental ischemia/hypoxia induced in animals by reduced uterine perfusion pressure (RUPP) or in humans stimulates release of hypertensive placental factors...

Journal: :Hypertension 2015
Fiona C Brownfoot Stephen Tong Natalie J Hannan Natalie K Binder Susan P Walker Ping Cannon Roxanne Hastie Kenji Onda Tu'uhevaha J Kaitu'u-Lino

UNLABELLED Preeclampsia is a major pregnancy complication where excess placental release of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin causes maternal endothelial and multisystem organ injury. Clinical trials have commenced examining whether pravastatin can be used to treat preeclampsia. However, the preclinical evidence supporting pravastatin as a treatment is limited to ...

Journal: :American journal of physiology. Regulatory, integrative and comparative physiology 2011
Eric M George Marietta Arany Kathy Cockrell Megan V Storm David E Stec Joey P Granger

Preeclampsia (PE) is one of the leading causes of fetal and maternal morbidity, affecting 5-10% of all pregnancies, and lacks an effective treatment. The exact etiology of the disorder is unclear, but placental ischemia has been shown to be a central causative agent. In response to placental ischemia, the antiangiogenic protein fms-like tyrosine kinase-1 (sFlt-1), a VEGF antagonist, and reactiv...

Journal: :The New England journal of medicine 2004
Alfredo Leaños-Miranda Inova Campos-Galicia María Guadalupe Berumen-Lechuga Carlos José Molina-Pérez Yolanda García-Paleta Irma Isordia-Salas Karla Leticia Ramírez-Valenzuela

OBJECTIVE To investigate whether angiogenic factors are associated with risk of developing preeclampsia in pregnant women with systemic lupus erythematosus (SLE). METHODS We performed a nested case-control study within a cohort of SLE women with singleton pregnancies. The study included 42 patients with SLE who eventually developed preeclampsia and 75 normal SLE pregnancies. Serum samples wer...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید